Onconetix, Inc.

ONCO Nasdaq CIK: 0001782107

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 201 E. FIFTH STREET, CINCINNATI, OH, 45202
Mailing Address 201 E. FIFTH STREET, CINCINNATI, OH, 45202
Phone 513-620-4101
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

$18.57M
Total Liabilities
$-16.56
EPS

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement March 30, 2026 View on SEC
3 Initial insider ownership report March 27, 2026 View on SEC
3 Initial insider ownership report March 27, 2026 View on SEC
8-K Current report of material events March 27, 2026 View on SEC
8-K/A Current report amendment March 25, 2026 View on SEC
8-K Current report of material events March 24, 2026 View on SEC
10-K Annual financial report March 13, 2026 View on SEC
8-K Current report of material events February 12, 2026 View on SEC
8-K Current report of material events February 9, 2026 View on SEC
DEF 14A Definitive proxy statement January 2, 2026 View on SEC

Annual Reports

10-K March 13, 2026
  • Strategic pivot to focus on Proclarix, an advanced blood-based diagnostic test for prostate cancer, with EU approval and a U.S. partnership with LabCorp.
  • Potential strategic diversification into the AI-powered digital health sector through a Share Exchange Agreement with Realbotix.
View Analysis

Material Events

8-K Leadership Change March 24, 2026
High Impact
  • Appointment of David White as CEO to drive operational efficiency
  • Strengthened board oversight with the addition of financial expert Sammy Dorf
View Analysis
8-K Strategy Change February 9, 2026
High Impact
  • Shareholders approved a reverse stock split for Onconetix, Inc.
  • The primary objective is to boost the stock price above $1.00 to meet Nasdaq listing requirements and avoid delisting.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.